| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
464.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.86 - $18.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 17.6 |
| Insider 3/6 Months : 18.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
558,056 |
558,056 |
762,731 |
| Total Buy Value |
$0 |
$3,530,830 |
$3,530,830 |
$5,499,522 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
14 |
14 |
17 |
| Total Shares Sold |
7,293 |
307,293 |
307,293 |
307,293 |
| Total Sell Value |
$120,236 |
$1,916,619 |
$1,916,619 |
$1,916,619 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
3 |
8 |
8 |
8 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gad Thomas |
President and Chairman |
• • – |
2020-08-12 |
4 |
S |
$39.51 |
$513,637 |
I/I |
(13,000) |
654,000 |
|
-33% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-08-11 |
4 |
S |
$40.06 |
$1,482,042 |
I/I |
(37,000) |
667,000 |
|
-40% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-08-03 |
4 |
AS |
$36.51 |
$146,026 |
I/I |
(4,000) |
704,000 |
|
39% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-07-15 |
4 |
AS |
$40.06 |
$160,229 |
I/I |
(4,000) |
708,000 |
|
16% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-07-01 |
4 |
AS |
$42.04 |
$168,178 |
I/I |
(4,000) |
712,000 |
|
16% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-06-15 |
4 |
AS |
$43.45 |
$173,811 |
I/I |
(4,000) |
716,000 |
|
-10% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-06-04 |
4 |
AS |
$41.61 |
$166,444 |
I/I |
(4,000) |
720,000 |
|
-5% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-05-27 |
4 |
S |
$39.01 |
$1,950,460 |
I/I |
(50,000) |
724,000 |
|
-4% |
|
| Ahmed Mahiuddin |
Sr. VP and CSO |
• – – |
2020-05-26 |
4 |
S |
$39.38 |
$1,969,235 |
D/D |
(50,000) |
150,000 |
|
3% |
|
| Ahmed Mahiuddin |
Sr. VP and CSO |
• – – |
2020-05-19 |
4 |
S |
$39.24 |
$392,403 |
D/D |
(10,000) |
200,000 |
|
-1% |
|
| Ahmed Mahiuddin |
Sr. VP and CSO |
• – – |
2020-05-18 |
4 |
S |
$39.49 |
$769,675 |
D/D |
(19,492) |
210,000 |
|
-1% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-05-18 |
4 |
AS |
$39.65 |
$158,596 |
I/I |
(4,000) |
774,000 |
|
1% |
|
| Kruse Bo |
EVP, CFO, Secy & Treas. |
• – – |
2020-05-14 |
4 |
S |
$36.03 |
$1,363,533 |
I/I |
(37,847) |
0 |
|
3% |
|
| Kruse Bo |
EVP, CFO, Secy & Treas. |
• – – |
2020-05-14 |
4 |
S |
$36.03 |
$1,015,872 |
D/D |
(28,199) |
257,077 |
|
3% |
|
| Juan Moller San Pedro Claus |
Chief Executive Officer |
• • – |
2020-05-14 |
4 |
S |
$36.02 |
$5,012,995 |
I/I |
(139,154) |
657,303 |
|
3% |
|
| Kruse Bo |
EVP, CFO, Secy & Treas. |
• – – |
2020-05-13 |
4 |
S |
$37.88 |
$728,400 |
I/I |
(19,230) |
37,847 |
|
2% |
|
| Kruse Bo |
EVP, CFO, Secy & Treas. |
• – – |
2020-05-13 |
4 |
S |
$37.86 |
$557,517 |
D/D |
(14,724) |
285,276 |
|
2% |
|
| Juan Moller San Pedro Claus |
Chief Executive Officer |
• • – |
2020-05-13 |
4 |
S |
$37.75 |
$2,297,125 |
I/I |
(60,846) |
796,457 |
|
2% |
|
| Ahmed Mahiuddin |
Sr. VP & Chief Scientific Off |
• – – |
2020-05-13 |
4 |
S |
$37.64 |
$395,563 |
D/D |
(10,508) |
229,492 |
|
2% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-05-12 |
4 |
S |
$39.04 |
$1,951,935 |
I/I |
(50,000) |
778,000 |
|
3% |
|
| Ahmed Mahiuddin |
Sr. VP and CSO |
• – – |
2020-05-12 |
4 |
S |
$39.19 |
$783,776 |
D/D |
(20,000) |
240,000 |
|
3% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-05-01 |
4 |
AS |
$32.35 |
$129,404 |
I/I |
(4,000) |
828,000 |
|
22% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-04-13 |
4 |
AS |
$29.43 |
$117,711 |
I/I |
(4,000) |
832,000 |
|
45% |
|
| Juan Moller San Pedro Claus |
Chief Executive Officer |
• • – |
2020-03-17 |
4 |
B |
$17.22 |
$32,712 |
I/I |
1,900 |
1,900 |
2.66 |
117% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-03-16 |
4 |
AS |
$18.01 |
$72,041 |
I/I |
(4,000) |
836,000 |
|
111% |
|
249 Records found
|
|
Page 8 of 10 |
|
|
0.25 (2.11%) 
